Sophiris to Begin Dosing Patients in Phase 2b Study of Topsalysin for Prostate Cancer

Sophiris to Begin Dosing Patients in Phase 2b Study of Topsalysin for Prostate Cancer
Sophiris Bio has received a green light to begin dosing patients in a Phase 2b U.S. clinical trial of topsalysin (PRX302) for prostate cancer. The go-ahead was in the form of a Federal Drug Administration approval of a substance that Sophiris uses to dilute topsalysin, according to a press release. The therapy is for an enlarged prostate as well as cancer that has yet to spread from the prostate. The multi-center trial (NCT03081481) will eval
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *